vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.3倍（$200.5M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 2.2%，领先32.3%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 5.2%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $1.1M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -3.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
CPRX vs ROG — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $200.5M |
| 净利润 | $52.7M | $4.5M |
| 毛利率 | 82.9% | 32.2% |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | 2.2% |
| 营收同比 | 7.6% | 5.2% |
| 净利润同比 | -5.8% | 421.4% |
| 每股收益（稀释后） | $0.40 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $200.5M | ||
| Q4 25 | $152.6M | $201.5M | ||
| Q3 25 | $148.4M | $216.0M | ||
| Q2 25 | $146.6M | $202.8M | ||
| Q1 25 | $141.4M | $190.5M | ||
| Q4 24 | $141.8M | $192.2M | ||
| Q3 24 | $128.7M | $210.3M | ||
| Q2 24 | $122.7M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $52.7M | $4.6M | ||
| Q3 25 | $52.8M | $8.6M | ||
| Q2 25 | $52.1M | $-73.6M | ||
| Q1 25 | $56.7M | $-1.4M | ||
| Q4 24 | $55.9M | $-500.0K | ||
| Q3 24 | $43.9M | $10.7M | ||
| Q2 24 | $40.8M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 82.9% | 31.5% | ||
| Q3 25 | 84.7% | 33.5% | ||
| Q2 25 | 85.9% | 31.6% | ||
| Q1 25 | 87.3% | 29.9% | ||
| Q4 24 | 84.7% | 32.1% | ||
| Q3 24 | 85.0% | 35.2% | ||
| Q2 24 | 87.4% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 40.5% | 3.5% | ||
| Q3 25 | 44.7% | 7.3% | ||
| Q2 25 | 45.2% | -33.3% | ||
| Q1 25 | 44.8% | -0.2% | ||
| Q4 24 | 44.3% | -6.6% | ||
| Q3 24 | 39.6% | 6.9% | ||
| Q2 24 | 44.2% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 34.5% | 2.3% | ||
| Q3 25 | 35.6% | 4.0% | ||
| Q2 25 | 35.6% | -36.3% | ||
| Q1 25 | 40.1% | -0.7% | ||
| Q4 24 | 39.4% | -0.3% | ||
| Q3 24 | 34.1% | 5.1% | ||
| Q2 24 | 33.2% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.40 | $0.20 | ||
| Q3 25 | $0.42 | $0.48 | ||
| Q2 25 | $0.41 | $-4.00 | ||
| Q1 25 | $0.45 | $-0.08 | ||
| Q4 24 | $0.44 | $-0.04 | ||
| Q3 24 | $0.35 | $0.58 | ||
| Q2 24 | $0.33 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $1.2B |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $195.8M | ||
| Q4 25 | $709.2M | $197.0M | ||
| Q3 25 | $689.9M | $167.8M | ||
| Q2 25 | $652.8M | $157.2M | ||
| Q1 25 | $580.7M | $175.6M | ||
| Q4 24 | $517.6M | $159.8M | ||
| Q3 24 | $442.3M | $146.4M | ||
| Q2 24 | $375.7M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $954.3M | $1.2B | ||
| Q3 25 | $920.2M | $1.2B | ||
| Q2 25 | $856.0M | $1.2B | ||
| Q1 25 | $794.3M | $1.3B | ||
| Q4 24 | $727.6M | $1.3B | ||
| Q3 24 | $660.9M | $1.3B | ||
| Q2 24 | $608.7M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.5B | ||
| Q4 24 | $851.4M | $1.5B | ||
| Q3 24 | $772.0M | $1.5B | ||
| Q2 24 | $706.4M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $1.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 0.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.3% |
| 现金转化率经营现金流/净利润 | 0.85× | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | $5.8M | ||
| Q4 25 | $44.9M | $46.9M | ||
| Q3 25 | $32.4M | $28.9M | ||
| Q2 25 | $71.3M | $13.7M | ||
| Q1 25 | $60.0M | $11.7M | ||
| Q4 24 | $70.9M | $33.7M | ||
| Q3 24 | $72.9M | $42.4M | ||
| Q2 24 | $64.1M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $44.9M | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | $71.3M | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | $70.8M | $18.3M | ||
| Q3 24 | $72.6M | $25.2M | ||
| Q2 24 | $64.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 29.4% | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | 48.6% | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | 49.9% | 9.5% | ||
| Q3 24 | 56.4% | 12.0% | ||
| Q2 24 | 52.3% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | 0.1% | 8.0% | ||
| Q3 24 | 0.2% | 8.2% | ||
| Q2 24 | 0.0% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 0.85× | 10.20× | ||
| Q3 25 | 0.61× | 3.36× | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 3.96× | ||
| Q2 24 | 1.57× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
ROG
暂无分部数据
